Hemab Therapeutics (NASDAQ:COAG) Shares Down 7.5% – Should You Sell?

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) shares traded down 7.5% on Tuesday. The stock traded as low as $28.12 and last traded at $28.31. 119,924 shares traded hands during trading, a decline of 68% from the average daily volume of 375,300 shares. The stock had previously closed at $30.59.

Analysts Set New Price Targets

Several brokerages have commented on COAG. HC Wainwright increased their target price on Hemab Therapeutics from $52.00 to $60.00 and gave the company a “buy” rating in a research note on Tuesday, August 11th. Jefferies Financial Group lifted their price objective on Hemab Therapeutics from $39.00 to $47.00 and gave the stock a “buy” rating in a report on Monday, July 13th. Wedbush upped their target price on shares of Hemab Therapeutics from $55.00 to $64.00 and gave the company an “outperform” rating in a research note on Wednesday, August 12th. Finally, Weiss Ratings downgraded shares of Hemab Therapeutics from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, September 25th. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $51.40.

Hemab Therapeutics Stock Up 1.2%

The business’s fifty day moving average is $43.34. The firm has a market capitalization of $1.34 billion and a price-to-earnings ratio of -1.16.

Hemab Therapeutics (NASDAQ:COAG) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.80) EPS for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.17). On average, analysts expect that Hemab Therapeutics Holdings, Inc. will post -3.09 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Citadel Advisors LLC purchased a new position in shares of Hemab Therapeutics in the 2nd quarter worth $19,226,000. Braidwell LP purchased a new stake in shares of Hemab Therapeutics in the second quarter valued at $5,877,000. State Street Corp bought a new position in Hemab Therapeutics during the 2nd quarter valued at about $2,825,000. Opaleye Management Inc. bought a new position in shares of Hemab Therapeutics during the second quarter valued at approximately $1,750,000. Finally, The Manufacturers Life Insurance Company purchased a new stake in Hemab Therapeutics in the second quarter worth $688,000.

Hemab Therapeutics Company Profile

Hemab Therapeutics (NASDAQ: COAG) is a clinical-stage biopharmaceutical company developing treatments for serious and potentially life-threatening bleeding disorders. The company focuses on rare conditions for which existing therapies may be limited, inconvenient, or ineffective for some patients.

Hemab’s lead investigational program, HMB-001, is an engineered bispecific antibody designed to improve blood clotting by enhancing thrombin generation through inhibition of tissue factor pathway inhibitor.